Filing Flows › Enanta Pharmaceuticals (ENTA) › Q3 FY26 › vs Q2 FY26
Enanta Pharmaceuticals (ENTA) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Enanta Pharmaceuticals's revenue fell $2.8M (-16%) from $17.2M in Q2 FY26 to $14.4M in Q3 FY26.
Enanta Pharmaceuticals, Q3 FY26: revenue $14.4M (-22% year over year), operating margin -120.0%, net loss $19.5M, operating cash flow −$10.0M. The chart draws each line against Q2 FY26, the increases inside each band.
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $14.4M | $17.2M | −$2.8M | -16% |
| Net loss | $19.5M | $13.1M | $6.4M | +49% |
| Costs & expenses | $33.9M | $30.2M | $3.6M | +12% |
| Operating costs | $31.6M | $29.0M | $2.6M | +9% |
| Interest & other, net | $2.2M | $1.2M | $997K | +81% |
| Income tax | $36K | $7K | $29K | +414% |
| Research & development | $22.1M | $19.4M | $2.7M | +14% |
| General & admin | $9.5M | $9.6M | −$99K | -1% |
| Operating cash sources | $19.5M | $13.1M | $6.4M | +49% |
| Depreciation & amortization | $1.2M | $1.2M | −$24K | -2% |
| Share-based compensation | $3.7M | $3.7M | −$65K | -2% |
| Working capital & other | $4.7M | $978K | $3.7M | +377% |
| Cash used in operations | $10.0M | $7.2M | $2.8M | +39% |
| Net loss absorbed | $19.5M | $13.1M | $6.4M | +49% |
Questions
How much did Enanta Pharmaceuticals's revenue grow quarter over quarter in Q3 FY26?
Enanta Pharmaceuticals's revenue fell $2.8M (-16%) from $17.2M in Q2 FY26 to $14.4M in Q3 FY26.